Because AML localized in the bone niche can become resistant to venetoclax therapy47, a systemic model of MV4-11 that engrafts in the spine and femur of mice was used to assess venetoclax + MCL-1 inhibitor therapy. The gene discussed is MCL1; the disease is acute myeloid leukemia.